Role of Hypoxia-Inducible Factors (HIFs) in Respiratory Syncytial Virus Infection
缺氧诱导因子 (HIF) 在呼吸道合胞病毒感染中的作用
基本信息
- 批准号:10742170
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-16 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcuteAcute Lung InjuryAnemiaAnimal Cancer ModelAnimal ModelAntibody FormationAntiviral ResponseAutoimmunityB-LymphocytesCancer ModelCell SurvivalCellsCellular Metabolic ProcessChildChronicChronic Kidney FailureClinicalClinical TrialsCollagenComplexCytokine GeneDataDendritic CellsDepositionDevelopmentDiseaseDrug ModulationDrug usageElderlyEpithelial CellsExhibitsFlow CytometryFunctional disorderGene ExpressionGeneticGenetic TranscriptionGoalsHistopathologyHumanHypoxiaHypoxia Inducible FactorImmuneImmune responseIn VitroInbred BALB C MiceInfantInfectionInflammationInterleukin-10InvestigationKineticsKnowledgeLaboratoriesLicensingLower Respiratory Tract InfectionLungLung diseasesLung infectionsMacrophageMalignant NeoplasmsMediatingMetabolicMetabolic PathwayMolecularMucous body substanceMusOutcomePathogenesisPathogenicityPatientsPhase III Clinical TrialsPhenotypePlayPopulationProcessProductionProductivityProteinsPublicationsPulmonary InflammationRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsRespiratory syncytial virusRoleShapesSignal TransductionStructureT-LymphocyteTestingTherapeuticTranscription ProcessTranscriptional RegulationTransforming Growth Factor betaVaccinesViralViral PathogenesisViral Respiratory Tract InfectionVirionVirusVirus DiseasesVirus ReplicationWorkairway epitheliumairway remodelingantiviral immunitycancer typecytokinedrug developmentexperienceextracellularfactor Ahigh riskhypoxia inducible factor 1immune activationimmunoregulationimprovedin vivo Modelinhibitorlung injurymigrationmouse modelneutrophilnovelpharmacologicprotective effectpulmonary functionrespiratoryrespiratory virusresponseside effecttherapeutically effectivetissue regenerationvaccine access
项目摘要
PROJECT SUMMARY/ABSTRACT
Several viruses have been shown to induce metabolic reprogramming of host cells to establish productive
infections. One common mechanism utilized by viruses is the stabilization of hypoxia-inducible-factors (HIF).
The HIF complex, comprised of an inducible α subunit (HIF-1α or HIF-2α) and a constitutively expressed β
subunit (HIF-1β), is known to control diverse transcriptional processes in response to hypoxia and other disease
states. The use of both HIF inhibitors and stabilizers has been investigated in models of cancer, autoimmunity,
and non-infectious acute lung injury, with several compounds for both classes currently being tested in phase 3
clinical trials for a variety of clinical disorders. However, there are no publications describing the use of a HIF
specific inhibitors or stabilizers in in vivo models of viral infections. In vitro studies have suggested that inhibiting
HIF-1α could represent an effective anti-viral strategy, including against respiratory viruses such as respiratory
syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, our
preliminary data in a mouse model of RSV infection, the leading cause of severe acute lung illness in infants for
which there are no effective therapeutics or licensed vaccines, did not support this strategy, as we found that
inhibition of HIF-1α worsen clinical disease and favors viral replication, while stabilization of HIF proteins
improves clinical disease and lung function. The central hypothesis of this application is that during RSV infection
(and possibly other respiratory viruses) HIFs mediate activation and survival of key immune cells that control
antiviral responses while maintaining lung integrity and function. We will test this hypothesis in a well-established
mouse model of RSV infection. In Specific Aim 1, we will determine the contributions of HIF-1α and/or HIF-2α to
RSV-mediated clinical disease, lung function, immune modulation, and viral replication using inhibitors specific
for each of the HIF-αsubunits. In Specific Aim 2, we will test the hypothesis that HIF stabilization protects the
airways from experimental RSV infection and modulate antiviral immune responses, using similar disease and
viral outcomes. This is a novel project with a long-term goal to uncover the unique and complex contribution of
HIFs to both antiviral immunity and lung pathophysiology, and with wider relevance for human respiratory
infections. This contribution is significant as these studies will provide important new information for ongoing
clinical trials of HIF inhibitors, used in patients with cancers and other diseases who could be at higher risk for
more severe respiratory viral infections, as well the potential use of HIF stabilizers as therapeutic approach for
respiratory virus associated lung diseases.
项目总结/摘要
已经显示几种病毒诱导宿主细胞的代谢重编程以建立生产性的细胞。
感染.病毒利用的一种常见机制是稳定缺氧诱导因子(HIF)。
HIF复合物由一个可诱导的α亚基(HIF-1α或HIF-2α)和一个组成性表达的β亚基组成,
已知HIF-1β亚基(HIF-1β)在响应缺氧和其它疾病中控制多种转录过程
states. HIF抑制剂和稳定剂两者的使用已经在癌症、自身免疫、
和非感染性急性肺损伤,目前正在第3阶段测试这两类化合物
针对各种临床疾病的临床试验。然而,没有出版物描述HIF的使用
特异性抑制剂或稳定剂在体内病毒感染模型中的应用。体外研究表明,
HIF-1α可能是一种有效的抗病毒策略,包括对抗呼吸道病毒,如呼吸道病毒。
合胞病毒(RSV)和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。但我们的
RSV感染小鼠模型的初步数据,RSV感染是婴儿严重急性肺部疾病的主要原因,
没有有效的治疗方法或许可的疫苗,并不支持这种策略,因为我们发现,
抑制HIF-1α使临床疾病恶化并有利于病毒复制,而稳定HIF蛋白
改善临床疾病和肺功能。本申请的中心假设是在RSV感染期间,
(and可能是其他呼吸道病毒)HIFs介导关键免疫细胞的激活和存活,
同时维持肺的完整性和功能。我们将在一个公认的
RSV感染的小鼠模型。在具体目标1中,我们将确定HIF-1α和/或HIF-2α对
使用特异性抑制剂的RSV介导的临床疾病、肺功能、免疫调节和病毒复制
每一个HIF-α亚基。在具体目标2中,我们将测试HIF稳定化保护细胞的假设。
气道从实验RSV感染和调节抗病毒免疫反应,使用类似的疾病和
病毒结果。这是一个新颖的项目,其长期目标是揭示
HIFs与抗病毒免疫和肺病理生理学,以及与人类呼吸系统疾病更广泛的相关性,
感染.这一贡献是重要的,因为这些研究将为正在进行的研究提供重要的新信息。
HIF抑制剂的临床试验,用于癌症和其他疾病患者,这些患者可能有更高的风险,
更严重的呼吸道病毒感染,以及HIF稳定剂作为治疗方法的潜在用途,
呼吸道病毒相关的肺部疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Antonella Casola其他文献
Antonella Casola的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Antonella Casola', 18)}}的其他基金
Hydrogen Sulfide and NRF2 Cross-talk in Viral Infections
病毒感染中的硫化氢和 NRF2 串扰
- 批准号:
9911341 - 财政年份:2019
- 资助金额:
$ 24万 - 项目类别:
Hydrogen Sulfide and NRF2 Cross-talk in Viral Infections
病毒感染中的硫化氢和 NRF2 串扰
- 批准号:
9843442 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
Hydrogen Sulfide and NRF2 Cross-talk in Viral Infections
病毒感染中的硫化氢和 NRF2 串扰
- 批准号:
10379874 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
A novel role of NF-kB in viral-induced airway oxidative stress
NF-kB 在病毒诱导的气道氧化应激中的新作用
- 批准号:
8784185 - 财政年份:2013
- 资助金额:
$ 24万 - 项目类别:
A novel role of NF-kB in viral-induced airway oxidative stress
NF-kB 在病毒诱导的气道氧化应激中的新作用
- 批准号:
8638667 - 财政年份:2013
- 资助金额:
$ 24万 - 项目类别:
Innate Immune Response to Human Metapneumovirus Infection
对人类偏肺病毒感染的先天免疫反应
- 批准号:
8661692 - 财政年份:2010
- 资助金额:
$ 24万 - 项目类别:
Innate Immune Response to Human Metapneumovirus Infection
对人类偏肺病毒感染的先天免疫反应
- 批准号:
7785949 - 财政年份:2010
- 资助金额:
$ 24万 - 项目类别:
Innate Immune Response to Human Metapneumovirus Infection
对人类偏肺病毒感染的先天免疫反应
- 批准号:
8473152 - 财政年份:2010
- 资助金额:
$ 24万 - 项目类别:
Innate Immune Response to Human Metapneumovirus Infection
对人类偏肺病毒感染的先天免疫反应
- 批准号:
8282740 - 财政年份:2010
- 资助金额:
$ 24万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别: